Alisertib Explained

Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda.[1] It was investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma.[2] [3] Development was abandoned in 2015 due to poor clinical trial results.[4]

Notes and References

  1. Friedberg. JW. Mahadevan . D . Cebula . E . Persky . D . Lossos . I . Agarwal . AB . Jung . J . Burack . R . Zhou . X . Leonard . EJ . Fingert . H . Danaee . H . Bernstein . SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.. Journal of Clinical Oncology. Jan 1, 2014. 32. 1. 44–50. 24043741. 10.1200/JCO.2012.46.8793. 3867644.
  2. Web site: Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma. Takeda Pharmaceutical Company Limited; Millennium Pharmaceuticals, Inc.. 20 March 2014. March 6, 2012.
  3. Web site: Research and Development Pipeline (As of February 5, 2014). Takeda Pharmaceutical Company Limited. 20 March 2014. 2. February 5, 2014.
  4. Web site: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alisertib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.